相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models
Romain Sigaud et al.
NEURO-ONCOLOGY (2023)
TXNIP: A Double-Edged Sword in Disease and Therapeutic Outlook
Min Pan et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2022)
Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications
Mohammad Askandar Iqbal et al.
FEBS JOURNAL (2021)
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Vikki Flemington et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
Babak Moghimi et al.
NATURE COMMUNICATIONS (2021)
NTRK1/TrkA Signaling in Neuroblastoma Cells Induces Nuclear Reorganization and Intra-Nuclear Aggregation of Lamin A/C
Lukas Funke et al.
CANCERS (2021)
Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes
Timofey Lebedev et al.
ONCOGENE (2021)
Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell Leukemogenesis
Jue Jiang et al.
CANCER CELL (2020)
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Andrea Varga et al.
CLINICAL CANCER RESEARCH (2020)
Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art
Karina Smorodinsky-Atias et al.
CELLS (2020)
A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Colin Weekes et al.
ONCOLOGIST (2020)
NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma
Ivette Valencia-Sama et al.
CANCER RESEARCH (2020)
OTUD5 cooperates with TRIM25 in transcriptional regulation and tumor progression via deubiquitination activity
Fangzhou Li et al.
NATURE COMMUNICATIONS (2020)
Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma
Ruiqi Liu et al.
CANCER LETTERS (2019)
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)
Ying Z. Mazzu et al.
CLINICAL CANCER RESEARCH (2019)
UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP
Dian Jiao et al.
ONCOGENE (2019)
Programmed expression of pro-apoptotic BMCC1 during apoptosis, triggered by DNA damage in neuroblastoma cells
Mohammad Sazzadul Islam et al.
BMC CANCER (2019)
Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling
Hui Li et al.
CANCER LETTERS (2019)
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma
Xin Xu et al.
CLINICAL CANCER RESEARCH (2019)
STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets
Damian Szklarczyk et al.
NUCLEIC ACIDS RESEARCH (2019)
ERK Inhibitor Enhances Everolimus Efficacy through the Attenuation of dNTP Pools in Renal Cell Carcinoma
Yun Zou et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies
Boaz Mendzelevski et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Capsaicin and Piperine Can Overcome Multidrug Resistance in Cancer Cells to Doxorubicin
Hanmei Li et al.
MOLECULES (2018)
Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
Hongmei Jiang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma (Vol8,pg19,2017)
Gabriella Cunha Vieira et al.
ONCOTARGET (2017)
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Ursula A. Germann et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells
Yuan Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein
Shin Yee Hong et al.
CELLULAR SIGNALLING (2016)
Paradoxical overexpression of MBNL2 in hepatocellular carcinoma inhibits tumor growth and invasion
Yu-Hsin Lee et al.
ONCOTARGET (2016)
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld et al.
NATURE GENETICS (2015)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
Siwen Hu-Lieskovan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
BMCC1, which is an interacting partner of BCL2, attenuates AKT activity, accompanied by apoptosis
Y. Tatsumi et al.
CELL DEATH & DISEASE (2015)
SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer
Lei Liu et al.
PLOS ONE (2015)
LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma
Gabriella Cunha Vieira et al.
ONCOTARGET (2015)
SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells
Ling Li et al.
CELL STEM CELL (2014)
Effects of vitamin D3 stimulation of thioredoxin-interacting protein in hepatocellular carcinoma
James P. Hamilton et al.
HEPATOLOGY RESEARCH (2014)
Epigenetic high regulation of ATAD2 regulates the Hh pathway in human hepatocellular carcinoma
Gang Wu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Inhibition of c-Myc Overcomes Cytotoxic Drug Resistance in Acute Myeloid Leukemia Cells by Promoting Differentiation
Xiao-Na Pan et al.
PLOS ONE (2014)
Cell Survival Signaling in Neuroblastoma
Michael L. Megison et al.
Anti-Cancer Agents in Medicinal Chemistry (2013)
RRM2 Regulates Bcl-2 in Head and Neck and Lung Cancers: A Potential Target for Cancer Therapy
Mohammad Aminur Rahman et al.
CLINICAL CANCER RESEARCH (2013)
Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma
John Shyi Peng Yuen et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Reversible adaptive plasticity: a mechanism for neuroblastoma cell heterogeneity and chemo-resistance
Lina Chakrabarti
Frontiers in Oncology (2012)
MYCN/MYC-mediated drug resistance mechanisms in neuroblastoma
S. Gogolin et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy
Stephen L. Abrams et al.
CELL CYCLE (2010)
Sept4/ARTS is required for stem cell apoptosis and tumor suppression
Maria Garcia-Fernandez et al.
GENES & DEVELOPMENT (2010)
Expression of Lgr5 in human colorectal carcinogenesis and its potential correlation with β-catenin
Xiang-Shan Fan et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2010)
ATAD2 Is a Novel Cofactor for MYC, Overexpressed and Amplified in Aggressive Tumors
Marco Ciro et al.
CANCER RESEARCH (2009)
ConsensusPathDB-a database for integrating human functional interaction networks
Atanas Kamburov et al.
NUCLEIC ACIDS RESEARCH (2009)
G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation
Keiji Tanese et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification
X. Liu et al.
ONCOGENE (2008)
Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway
Ziqiu Wang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas
T Machida et al.
ONCOGENE (2006)
Neural precursor cycling at sonic speed - N-Myc pedals, GSK-3 brakes
PS Knoepfler et al.
CELL CYCLE (2006)
Targeting the ERK signaling pathway in cancer therapy
M Kohno et al.
ANNALS OF MEDICINE (2006)
Erk associates with and primes GSK-3β for its inactivation resulting in upregulation of β-catenin
QQ Ding et al.
MOLECULAR CELL (2005)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma
Y Ren et al.
ONCOGENE (2004)
Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization
N Fujita et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells
JK Oosterhoff et al.
ONCOGENE (2003)
Overexpression of orphan G-Protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with β-catenin mutations
Y Yamamoto et al.
HEPATOLOGY (2003)
Neuroblastoma: Biological insights into a clinical enigma
GM Brodeur
NATURE REVIEWS CANCER (2003)
All kinesin superfamily protein, KIF, genes in mouse and human
H Miki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
